VYVoyager Therapeutics VYGR · NASDAQ
$1.74 -6.45% (-$0.12)
- Market cap
- $126.3M
- Enterprise value
- $123.1M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 3.7x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -62.4%
- Gross margin
- -104.2%
- Net margin
- -312.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.28
- Free float
- 83.7%
About the company
Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing therapeutic products for neurological disorders. With a deep understanding of the brain and nervous system, Voyager Therapeutics aims to transform the treatment of these complex diseases through gene therapy. Their research focuses on utilizing adeno-associated viruses to deliver therapeutic genes to the brain and restore normal functions. The company seeks to provide new possibilities for patients with neurodegenerative diseases. Voyager Therapeutics, Inc. (VYGR) shares could be suitable for investors who wish to support innovative developments in treatment approaches within the field of neurology and contribute to improving the quality of life for patients.
Sector
Healthcare
Industry
Biotechnology
CEO
Alfred W. Sandrock Jr.
Employees
141
Headquarters
Lexington
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number